(Geyer C E, Sikov W M, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial[J]. Annals of Oncology, 20...
BRCA1/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impactsBreast Cancer Association Consortium (BCAC)BRCAX CasesPhosphodiesterase 3B (PDE7B)Single Nucleotide Polymorphisms (SNPs)
[4]Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLAstudy)[J]. Ann ...
乳腺癌分为多种亚型,三阴性乳腺癌(triple negative breast cancer, TNBC)是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2)均为阴性的一种乳腺癌。临床数据显示,三阴性乳腺癌占所有乳腺癌病理类型的15%-23.8%。 三阴性乳腺癌被认...
Caputo R, Pagliuca M, Pensabene M, Parola S, De Laurentiis M. Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report. Front Oncol. 2023 Aug 4;13:1214660. doi: 10.3389/fonc.2023.1214660. PMID: 37601649; ...
乳腺癌分为多种亚型,三阴性乳腺癌(triple negative breast cancer, TNBC)是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2)均为阴性的一种乳腺癌。临床数据显示,三阴性乳腺癌占所有乳腺癌病理类型的15%-23.8%。 三阴性乳腺癌被认为是乳腺癌类型中的凶险之最,具有侵袭力强、恶性程度高的特点,...
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report. Front Oncol. 2023 Aug 4;13:1214660. doi: 10.3389/fonc.2023.1214660. PMID: 37601649; PMCID: PMC10438988....
乳腺癌分为多种亚型,三阴性乳腺癌(triple negative breast cancer, TNBC)是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2)均为阴性的一种乳腺癌。临床数据显示,三阴性乳腺癌占所有乳腺癌病理类型的15%-23.8%。 三阴性乳腺癌被认为是乳腺癌类型中的凶险之最,具有侵袭力强、恶性程度高的特点,...
https://blog./insight/2019/05/is-brca-positive-breast-cancer-treated-differently-from-brca-negative/ 专注肿瘤与重大疾病 不片面为了寻求合作而与医院签署转诊患者数量条款,坚持结合医院优势,从患者病情角度推荐更好的医院和专家 不接受短期逐利资本投资,避免被资本绑架 ...
乳腺癌分为多种亚型,三阴性乳腺癌(triplenegativebreastcancer,TNBC)是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2)均为阴性的一种乳腺癌。临床数据显示,三阴性乳腺癌占所有乳腺癌病理类型的15%-23.8%。 三阴性乳腺癌被认为是乳腺癌类型中的凶险之最,具有侵袭力强、恶性程度高的特点,并且内脏...